| 1.58 -0.13 (-7.6%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.45 | 1-year : | 2.86 |
| Resists | First : | 2.09 | Second : | 2.45 |
| Pivot price | 1.74  |
|||
| Supports | First : | 1.4 | Second : | 0.97 |
| MAs | MA(5) : | 1.74 |
MA(20) : | 1.56 |
| MA(100) : | 1.36 |
MA(250) : | 1.3 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 61.6 |
D(3) : | 68 |
| RSI | RSI(14): 52.4 |
|||
| 52-week | High : | 3.15 | Low : | 0.77 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ESLA ] has closed above bottom band by 19.8%. Bollinger Bands are 15.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.71 - 1.73 | 1.73 - 1.74 |
| Low: | 1.47 - 1.49 | 1.49 - 1.5 |
| Close: | 1.56 - 1.58 | 1.58 - 1.6 |
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Wed, 22 Apr 2026
Estrella Immunopharma (ESLA) Management Strategy | Q1 2026: Below Expectations - Strong Sell - Cổng thông tin điện tử tỉnh Tây Ninh
Tue, 21 Apr 2026
Robinson Opportunistic Income Fund's Estrella Immunopharma Inc(ESLAW) Holding History - GuruFocus
Mon, 20 Apr 2026
Estrella Immunopharma (ESLA) Stock Dividend Yield (Drifts Lower) 2026-04-20 - Most Discussed Stocks - Xã Vĩnh Công
Thu, 16 Apr 2026
Estrella Immunopharma (ESLA) Stock: Increase Exposure? (Dips) 2026-04-16 - Trending Volume Leaders - Cổng thông tin điện tử Tỉnh Sơn La
Mon, 06 Apr 2026
Is Estrella Immunopharma (ESLA) Stock Showing Weakness | Price at $1.25, Up 19.05% - Elite Trading Signals - Xã Thanh Hà
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 61.1 (%) |
| Held by Institutions | 2.4 (%) |
| Shares Short | 626 (K) |
| Shares Short P.Month | 639 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.28 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -258.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | -4.52 |
| PEG Ratio | 0 |
| Price to Book value | -5.86 |
| Price to Sales | 0 |
| Price to Cash Flow | -37.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|